Anemia and Transfusion Decisions in the Intensive Care Unit by Eliza Sherin Koshy,
 ANEMIA AND TRANSFUSION DECISIONS 
IN THE INTENSIVE CARE UNIT 
 
 
A dissertation submitted to the Tamil Nadu Dr. M.G.R. Medical 
University in partial fulfillment of the University regulations for the 
award of 
M . D .  I m m u n o  H a e m a t o l o g y  &  B l o o d  T r a n s f u s i o n  
( B r a n c h  –X X I )   
 
 
 
 
 
 
DEPARTME NT O F  TR ANSFUSIO N ME DICI NE  AND  IMMUNO HAEM AT OLOGY  
CHRI STI AN ME DIC AL  COL LEGE ,  VELLORE  
 
 BONAFIDE CERTIFICATE 
 
 
 
This is to certify that the work presented in this dissertation titled “Anemia and 
Transfusion Decisions in the Intensive Care Unit ” done towards fulfillment 
of the requirements of the Tamil Nadu Dr. M.G.R. Medical University, 
Chennai for the M.D. Immuno Haematology & Blood Transfusion  
(Branch– XXI ) exams to be conducted in April 2014, is a bonafide work of 
the candidate Dr. Eliza Sherin Koshy, Post graduate student in the Department 
of Transfusion Medicine and Immunohaematology, Christian Medical College, 
Vellore done under my supervision.  This dissertation has not been submitted, 
fully or in part to any other board or University. 
 
 
  
Dr. Sukesh C Nair,  
Head of Department, 
Department of Transfusion Medicine and Immunohaematology,  
Christian Medical College, Vellore – 632004 
 
 BONAFIDE CERTIFICATE 
 
 
 
This is to certify that the work presented in this dissertation titled “Anemia and 
Transfusion Decisions in the Intensive Care Unit ” done towards fulfillment 
of the requirements of the Tamil Nadu Dr. M.G.R. Medical University, 
Chennai for the M.D. Immuno Haematology & Blood Transfusion  
(Branch– XXI ) exams to be conducted in April 2014, is a bonafide work of 
the candidate Dr. Eliza Sherin Koshy, Post graduate student in the Department 
of Transfusion Medicine and Immunohaematology, Christian Medical College, 
Vellore done under my guidance and supervision.  This dissertation has not 
been submitted, fully or in part to any other board or University. 
 
 
Guide.:  
Dr. Dolly Daniel,  
Professor, 
Department of Transfusion Medicine and Immunohaematology,  
Christian Medical College, Vellore –  632004 
 
 
 PLAGIARISM 
 
 
 
 
 
 
 
 
 Acknowledgments 
Working on this thesis has been a very challenging, yet worthwhile experience. I am truly 
indebted to all the people who have helped me throughout this period. 
First and foremost, I am extremely thankful to my Professor and my guide, Dr. Dolly Daniel 
for her encouragement, wisdom, knowledge and guidance at all stages of this thesis. Her 
constant support has made this dissertation a reality. 
Next, I would like to thank my Co-Guide, Dr. J.V.Peter, for his valuable suggestions and 
insights during the time of my study. I would also like to thank him for compiling and 
analyzing all my data. 
My sincere thanks to Dr.Sukesh Chandran, Professor and Head of Department, Dr. Joy 
Mammen, Professor, Dr.Mary Purna Chacko,Associate Professor and my colleagues‟ for 
their valuable advice. 
I would also like to thank Ms.Gowri from Biostatistics for her help in analyzing the data. 
I am also indebted to my husband for his help and support, and my son who had been very 
patient and understanding all through my work on this dissertation. 
Above all, I thank God for His unmerited favor in every area of my life. 
 
 CONTENTS 
 
 
TITLE PAGE NO 
Abbreviations I 
List of Tables Iii 
List of Figures Iv 
Abstract V 
INTRODUCTION 1 
AIMS AND OBJECTIVES 4 
REVIEW OF LITERATURE 6 
MATERIAL AND METHODS 52 
RESULTS 56 
SUMMARY OF RESULTS 77 
DISCUSSION 81 
CONCLUSION 87 
BIBLIOGRAPHY  
ANNEXURES  
 
 
i 
 
ABBREVIATION 
 
Hb                     Haemoglobin 
RBC                  Red Blood Cell 
MICU               Medical Intensive Care Unit 
SICU                 Surgical Intensive Care Unit 
WHO                World Health Organization 
PO2                   Partial Pressure of oxygen 
P50                    Partial pressure of oxygen at 50% saturation 
PCO2                Partial pressure of carbon dioxide 
2,3-DPG            2,3 Di-phosphoglycerate 
DO2                  Oxygen delivery 
CaO2                Arterial oxygen content 
VO2                  Oxygen consumption 
EPO                  Erythropoeitin 
rHuEPO            Recombinant Human erythropoietin 
TNF                  Tumour Necrosis Factor 
IL                      Interleukin  
SA                     Sialic acid 
IDA                   Iron deficiency anemia 
AI                      Anemia of inflammation 
APACHE          Acute Physiological and Chronic Health Evaluation Score 
SOFA                Systemic Organ Failure Assessment Score 
ii 
 
 
FNHTR             Febrile Non Haemolytic Transfusion Reactions 
TRALI              Transfusion Related Acute Lung Injury 
TACO               Transfusion Associated Circulatory Overload 
TA-GVHD        Transfusion associated Graft vs Host Disease 
TRIM                Transfusion Related Immunomodulation 
HLA                  Human Leukocyte Antigen 
HPA                  Human Platelet Antigen 
ABC Trial         Anemia and Blood Transfusion in Critical Care 
TRICC              Transfusion Requirements in Critical Care 
SOAP                Sepsis Occurrence in Acutely Ill Patients 
ATICS              Audit of Transfusion in Intensive Care Study 
 
 
 
 
 
 
 
 
iii 
 
LIST OF TABLES 
TABLE  TITLE PAGE  
1 Overall characteristics of patients in the study population 57 
2 Baseline characteristics of MICU and SICU patients 59 
3 Overall outcome of ICU stay                                                                  61 
4 Comparison of outcome among the ICUs                                             62 
5 Mean pre transfusion haemoglobin trigger in both ICU‟s.                   65 
6 Association between transfusion and mortality in MICU and SICU  66 
7 Association of transfusion with any blood or product with ICU         
and hospital stay                                                                               
67 
8 Association of packed cell transfusions with ICU and hospital stay   68 
9 Association of packed cell transfusions with hospital length of stay in  
MICU and SICU patients 
69 
10 Association of age and APACHE II score with transfusion 71 
11 Baseline haemoglobin among the transfused and non transfused 72 
12 Univariate analysis for risk factors of overall mortality 73 
13 Univariate analysis for risk factors of mortality in MICU and SICU 74 
14 Multivariate analysis for risk factors of overall mortality 75 
15 Multivariate analysis for risk factors of mortality in MICU and SICU 76 
16 Comparison of data of current study with other studies            85 
iv 
 
LIST OF FIGURES 
FIGURE  FIGURE LEGEND PAGE  
1 Oxyhaemoglobin dissociation curve 9 
3 Transfusion reactions 27 
4 Complement activation during Hemolytic Transfusion Reactions 29 
5 Electron microscopic pictures of RBC storage lesion 38 
6 Distribution of patients in the study population 56 
7 Percentage of co morbid conditions in both ICUs 59 
8 Admitting diagnosis in MICU 60 
9 Admitting diagnosis in SICU 60 
10 Transfusions in MICU and SICU 63 
11 Overall indications for packed cell transfusions 64 
12 RBC transfusions across MICU stay 67 
13 Haemoglobin levels in MICU from Day 1 through Day 16 70 
14 Haemoglobin levels in SICU from Day 1 through Day 13 71 
 
 
v 
 
ABSTRACT 
 
ANEMIA AND TRANSFUSION DECISIONS IN THE INTENSIVE CARE UNIT 
 
Background: Anemia is frequently seen in critically-ill patients contributing to increased 
morbidity, mortality, and hospital stay. 
In ICU, anemia is treated with allogenic blood transfusions. Audits show 95% of ICU 
patients have haemoglobin level below normal by ICU day-3 and 50% of critically-ill 
patients receive RBC transfusions, trigger being 8.5g/dl. Higher transfusion rates were 
associated with prolonged ICU stay. 
Aim: To study transfusion thresholds and practices in Indian intensive care unit patients. 
Materials and Methods: Patients admitted during October 2012-June 2013 to medical and 
surgical-ICU, with an anticipated stay greater than 48hrs were enrolled. Patients with known 
primary haematological disorder or who succumb to their illness or discharged within 24hrs 
of ICU admission were excluded. Patients were followed up throughout their stay until 
hospital discharge or if death occurred before that. Data collection included admission 
haemoglobin along with daily hemoglobin values, requirement of RBC transfusions with 
indication, pre-transfusion haemoglobin, length of ICU and hospital stay and outcome. 
Results: 800 patients were enrolled. Overall, 38% of patients received transfusions with 
blood or blood products and 34% of patients received RBC transfusions. Most common 
indication for transfusion was a drop in haemoglobin without overt bleeding, mean pre 
vi 
 
transfusion trigger was 7.0±1.6 g/dl. Mortality was 23% among those who did not receive 
transfusions and 30% among those who received packed cells. There was a statistically 
significant association between packed cell transfusions and prolonged ICU and hospital 
stay. Mean baseline haemoglobin was 10.7±2.8g/dl. Hemoglobin levels decreased throughout 
the duration of ICU stay. There was a statistically significant association between age, 
APACHE-II score, duration of ventilation and packed cell transfusion with mortality. After 
adjusting for other risk factors, APACHE-II score and ventilation duration remained 
significantly associated with increased mortality but no association was seen between receipt 
of RBC transfusion and mortality. 
Conclusion: There was a significant drop in haemoglobin following admission to ICU. RBC 
transfusions were initiated below 7g/dl. Transfusion led to prolonged ICU and hospital stay 
and mortality in the transfused was significantly higher than in the non-transfused. 
Approaches should therefore be made to reduce RBC transfusions in critically-ill patients. 
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INTRODUCTION 
Anemia has been recognized as a frequent complication in the critically ill patient. It leads to 
a decrease in the oxygen carrying capacity of blood resulting in increased morbidity and 
mortality, and a prolonged length of stay in the hospital. 
The causes for anemia are multifactorial and include hemodilution, frequent blood sampling 
for laboratory investigations, hemorrhage, bone marrow suppression, inadequate 
erythropoietin response and increased RBC destruction due to complement activation in 
critically ill patients. 
In the intensive care setting, anemia is commonly treated with allogenic blood transfusion, 
the primary aim being to increase the oxygen delivery, determined by an increase in the 
cardiac output and oxygen content of arterial blood, which is in turn dependant on the 
haemoglobin level. 
Several audits have found that approximately 95% of ICU patients have haemoglobin level 
less than normal by the third day of their ICU stay and roughly 50% of the  patients receive 
packed cell transfusions during their ICU stay. Several landmark studies have examined 
anemia in the ICU setting and they reveal a number of similarities. 
1. Majority of the ICU patients are anemic on admission. 
2. The transfusion trigger in most studies was a hemoglobin level of about 8.5g/dl. 
3. The commonest indication for initiating transfusion was anemia. 
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4. A more restrictive transfusion strategy was probably safer than a liberal transfusion 
strategy and hospital mortality was much lesser in the restrictive arm of patients. 
5. Greater number of packed cell transfusions was associated with a lengthened ICU 
stay. 
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AIM & OBJECTIVES 
 
AIM 
 To study thresholds for transfusion and transfusion practices in Indian intensive care 
unit patients. 
OBJECTIVES 
1. Prevalence of anemia at admission and haemoglobin trends during ICU stay 
2. To ascertain transfusion thresholds and transfusion practices in ICU patients 
3. To assess if transfusion is an independent factor associated with mortality. 
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REVIEW OF LITERATURE 
Anemia is a prevailing problem and a frequent complication encountered in critically-ill 
patients. Its  incidence from various observational studies is roughly 95% in patients who 
have for more than three days in the intensive care unit.(1) 
DEFINITION: 
Anemia is a state of pathological insufficiency in the oxygen-carrying capacity of blood.  It 
can be calculated as unit volume concentrations of hemoglobin, volume of red blood cells, or 
the number of red blood cells.  
The World Health Organization (WHO) defines anemia as a haemoglobin concentration that 
is below the normal range, which refers to the distribution of haemoglobin in a large 
representative set of individuals.  
Historically, anemia is defined as a decrease in hemoglobin (less than 12 g/dl for women, 
less than 13 g/dl for men) and hematocrit (less than 36% for women and less than 39% for 
men) .In the ICU patient, typically quoted figures are a hemoglobin < 10 g/dl or a hematocrit 
< 30%.(2) 
ERYTHROPOESIS: 
Erythropoiesis is the process of development of mature red blood cells (erythrocytes). All 
blood cells including RBCs start as stem cells. The foremost cell recognized that specifically 
leads down the RBC path is called the proerythroblast. As it develops, the nucleus becomes 
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smaller, with the cytoplasm being more basophilic because of the appearance of ribosomes. 
As hemoglobin begins to be produced the cell, the cytoplasm of the cell attracts basic and 
eosin stains, hence the name, polychromatophilic erythroblast. Following this, the cytoplasm 
becomes more eosinophilic, and becomes an orthochromatic erythroblast. This erythroblast 
thereafter extrudes its nucleus and becomes a reticulocyte which enters the circulation. These 
reticulocytes contain small fragments and remnants of basophilic material including 
mitochondria and other organelles. When the reticulocytes lose these basophilic remnants 
(over 1 to 2 days), they become mature RBCs.  
Older and damaged RBCs are constantly removed from the circulation primarily by the 
spleen, and the cell components (i.e., iron from hemoglobin) are further recycled to form new 
RBCs. Erythropoiesis requires a normal supply of substrates (vitamins B12 and folate), 
nutrients, and essential minerals (iron). 
HAEMOGLOBIN 
 The major oxygen-carrying pigments of the body are hemoglobins. They are incorporated 
into red blood cells in adequate quantities to carry sufficient amount of oxygen from the 
lungs to the tissues to meet the needs of those cells for oxidative metabolism.  
Hemoglobins are composed of globin polypeptide chain tetramer. This contains a pair of 
alpha - chains which are 141 amino acids long and a pair of beta chains which are 146 amino 
acids long. HbA is the chief adult hemoglobin with a structure α 2β 2. The human 
hemoglobins are encoded in two gene clusters that are tightly linked. The alpha globin genes 
are present on chromosome 16, and the beta genes are present on chromosome 11. 
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Each globin chain encloses a single heme moiety, which consists of a protoporphyrin IX ring 
complexed with an iron atom in its ferrous state (Fe
2+
). Every heme moiety has the capacity 
to bind to a single molecule of oxygen. Therefore one hemoglobin molecule transports up to 
four molecules of oxygen The hemoglobin molecule is highly soluble but the individual 
globin chains are not soluble. Unpaired globin usually precipitates, forming inclusions that 
damage the cell. The normal globin chain synthesis is well balanced in that each newly 
synthesized alpha or non-alpha globin chain has a partner with which to pair.(3) 
The relationship between the oxygen content in the blood and the oxygen tension of blood is 
represented by the oxyhaemoglobin dissociation curve. Any given point on the sigmoid-
shaped curve represents the haemoglobin oxygen affinity at that particular point. The P50 is 
usually used as a symbol of haemoglobin oxygen affinity. It is described as the oxygen 
tension at 50% haemoglobin saturation. The factors that increase haemoglobin oxygen 
affinity shifts the oxyhaemoglobin dissociation curve to the left thereby decreasing the P50, 
and factors which increase haemoglobin oxygen affinity will shift the curve to the right 
increasing the P50. 
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Fig 1  Oxyhaemoglobin dissociation curve. Harrison’s Haematology and Oncology (4) 
For oxygen transport, hemoglobin should bind to oxygen efficiently at the partial pressure of 
oxygen (PO2) in the alveolus, thereafter retain and transport it to the tissues, and release it 
there at the PO2 of tissue capillary beds. The hemoglobin tetramer is fully deoxygenated at 
low oxygen tensions. As O2 tension rises oxygen binding begins slowly. But once some 
oxygen binds to the tetramer, there is an immediate increase in the slope of the curve. 
Therefore a higher oxygen affinity is exhibited by hemoglobin molecules that have bound 
some oxygen. This accelerates their ability of hemoglobin to combine with more oxygen. 
The affinity of hemoglobin for oxygen is also modulated by several other factors like pH, 
PCO2 and temperature. The effects of pH on the haemoglobin-oxygen affinity is referred to 
as the Bohr effect, this describes the intrinsic property of hemoglobin where by a molecule of 
Hb can accept an H+ when it releases a molecule of oxygen. Deoxyhaemoglobin can hold on 
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to and accepts the H+ better than oxyhaemoglobin. The affinity of haemoglobin for oxygen is 
reduced by increased H+ concentration, when the blood reaches the tissues that have higher 
concentrations of lactic acid and CO2. Oxygen is then released at these sites. Similarly an 
increase in temperature also decreases the affinity of haemoglobin for oxygen. 2,3-DPG a 
byproduct of the glycolytic pathway which occurs in the erythrocyte in similar concentrations 
as haemoglobin also lowers oxygen affinity when bound to hemoglobin.  
The functional capacity of the erythrocyte, requires normal renal production of 
erythropoietin, a functioning erythroid marrow, and a sufficient supply of substrates for 
hemoglobin synthesis. A defect or deficiency in any of these vital components can lead to 
anemia. 
Erythropoietin stimulation can lead to four to fivefold increase in production within a one to 
two week period, but this can happen only in the presence of adequate nutrients, especially 
iron. 
Principles of oxygen transport 
After dissolution in plasma, oxygen is transported after being bound to haemoglobin. Oxygen 
has a very low solubility in plasma and therefore transport by the process of diffusion is 
inefficient. In the non anemic patient with a Hb of about 14 gm/dl, most of the oxygen is 
haemoglobin-bound and a very small amount of approximately 2% only is found in a 
dissolved form in the plasma. On the contrary, in a patient with severe anemia, on 100% 
oxygen with a Hb of 5g/dl, we find that plasma contains almost 20% of dissolved oxygen. 
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Oxygen delivery (DO2) is a combined byproduct of cardiac output and measured arterial 
oxygen content represented as (CaO2). When represented as a formula:  
DO₂=cardiac output × CaO₂ (where CaO₂=(Hb×1.34×SaO₂)+(PaO₂×0.003) 
Likewise. oxygen consumption (VO2) is the byproduct of cardiac output and the arterio-
venous (difference) in content of oxygen.(5)(6) 
It is crucial to understand that a drop in the Hb level does not inevitably result in decreased 
DO2 because invariably cardiac output will increase. Alternate mechanisms which 
compensate are those which increase the oxygen extraction capacity thus lowering venous 
oxygen saturation and partial pressure. 
These two mechanisms help patients who are normovolemic to tolerate Hb levels up to 5 g/dl 
with no decrease in oxygen consumption or other clinical evidence of oxygen deprivation. In 
addition the redistribution of blood flow which happens when Hb levels are low, to ensure 
oxygenation of vital organs such as heart, brain and vital tissues and organs helps optimize 
clinical situations. 
Physiological adaptation to progressive normovolemic anemia 
Progressive anemia leads to reduction in blood viscosity, favoring the venous return to heart 
and facilitating ejection of stroke volume. Moreover, normovolaemic anaemia increases 
sympathetic stimulation of the heart, thereby contributing to an increase in the cardiac output. 
DO2 decreases during progressive normovolaemic anaemia in spite of an increase in the 
cardiac output. Nevertheless, oxygen extraction also increases, thereby VO2 continues to be 
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constant in even at haemoglobin of 5 g/dL. Hence with acute normovolemic anemia, the 
decrease in arterial oxygen content is compensated for by  
1) increasing the cardiac output,  
2) redistribution of blood flow between and within organs, and  
3) alteration in the amount of oxygen extracted from the blood. 
Following exhaustion of these compensatory mechanisms, tissue injury occurs. 
Microcirculatory changes take place as oxygen content decreases with progressive 
hemodilution, leading to a recruitment of capillaries. There is more time for gas exchange as 
the red cell capillary transit time increases. Moreover, anemia changes the oxygen extraction 
ratio from the RBC itself by increasing red cell 2,3-DPG and shifting the oxyhemoglobin 
dissociation curve to the right, so that more oxygen is released to the tissues. 
Animal studies have constantly confirmed that healthy animals can tolerate acute, isovolemic 
hemodilution up to 5 g/dL without any untoward consequences.(7) Any further hemodilution 
results in cardiac ischemia and reduced oxygen uptake. When hemoglobin levels fall below  
3g/dL, there is increased lactate production, decreased left ventricular function and cardiac 
output, and an increased risk of death. In healthy humans, the critical hemoglobin level is still 
unknown but  studies have found that it is likely to be less than 5 g/dL.(6) 
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Etiology of anaemia in critical illness 
The etiology of anaemia during critical illness can be due to a number of factors.(2) They can 
be divided into: 
 Pre-existing chronic anaemia and  
 Acquired anaemia.  
Among the causes for acquired anemia include: 
 Haemodilution 
Critically ill patients often develop intravascular hypovolaemia that require some amount of 
fluid resuscitation. Heamoglobin/haematocrit has been considered as customary clinical 
measure for anemia, but it cannot be used as a reliable estimate of red cell mass as it is 
affected by an alteration in the plasma volume. 
Haemodilution amounts for a considerable proportion of the fall in haemoglobin 
concentration that may occur rapidly during the early stages of critical illness, mostly during 
fluid resuscitation. 
 Blood loss/haemorrhage 
Studies in ICU patients have shown that the commonest cause for anemia in this setting is 
hemorrhage. Gastrointestinal bleeding or hemorrhage occurring due to trauma or surgery are 
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obviously evident but less overt hemorrhage, can occur due to various ICU interventions 
which may be not so easily detected.  
Repetitive blood sampling for investigations has often been cited as a cause for significant 
blood loss. Corwin at al. noted that blood loss due to phlebotomy amounted for almost 30% 
of the total number of units transfused in 142 ICU patients, with an increased blood loss 
owing to phlebotomy in those patients who were transfused (8). It was estimated that in the 
anemic critically-ill patients, the median blood loss was as high as 128 ml per day.  
The ABC trial estimated that the volume of blood lost through blood sampling, l amounted to 
41 ml per 24 h.(9) When calculated as per day losses this could amount to iron losses of 
64mg/day Considering that our daily iron ingestion is less than the estimated iron loss by 20 
fold it is highly likely that in this group of critically ill patients, , iron deficiency could set in.. 
 Anemia of inflammation 
Developing during states of inflammation, anemia of Inflammation (AI) is now the favored 
name for what was previously described as anemia of chronic disease. Following iron 
deficiency, it is the second most prevalent form of anemia seen The mechanisms responsible 
for this entity are four as mentioned below.: decreased production of erythropoietin (EPO), 
impaired  response of the bone marrow to EPO, reduced iron levels, and increased 
clearance of RBCs.(10) 
A mild to moderate normocytic, normochromic anemia associated with abnormal iron 
utilization is caused due to inflammation. 
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The characteristic feature of this disorder is a combination of a raised ferritin in combination 
with a low  serum iron and transferrin saturation.(11) An excess of hepcidin leading to 
inhibition of recycling of the iron by the macrophages is usually the cause. Inflammation 
(mediated by IL-1) leads to ferritin synthesis independent of the level of iron stores and 
hence elevated ferritin levels is no longer suggestive of iron stores in the presence of 
inflammation [10]. Thus, in spite of an iron profile mimicking iron overload, iron deficiency 
exists in these group of critically ill patients. Anemia owing to iron deficiency can also 
coexist with anemia of inflammation. 
The level of hepcidin may be a useful marker of IDA in the presence of anemia of 
inflammation since hepcidin is the key regulator of iron homeostasis. Levels of hepcidin 
markedly decrease in the presence of IDA and they are elevated in anemia of inflammation. 
 Reduced red cell production 
Erythropoiesis responds to changes in haemoglobin levels. And the process of erythropoiesis 
is a rather flexible one. It usually adapts to maintain a relatively constant Hb level. On a 
normal day only about 1% of circulating red cells are renewed. However, if there is an acute 
event such as acute blood loss, the rate of erythropoesis can compensate even up to 10 times. 
Sometimes, when the bone marrow does not produce adequate red cells, this response is 
blunted, and in addition there is a low reticulocyte response. 
In addition, factors which affect haematopoiesis such as stimulatory and inhibitory 
mediators, many which are related to inflammation will also impact on anemia and response 
to the same. Inhibitory mediators act by suppressing the production and action of stimulatory 
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factors, which results in preventing hematopoietic stem cells growth or by causing 
programmed cell death. Interferon(IFNɣ) (12), tumor necrosis factor (TNF) (13), 
transforming growth factor (TGF)-b (14), and interleukin-1 all have shown to inhibit the 
growth of erythropoeitic progenitor cells, and injection of these cytokines into healthy 
humans or animals can result in anemia (15). An important role in mediating these effects is 
also seen with Nitric oxide (NO).(16)(17)(18) 
The erythroid response to erythropoietin (EPO) administered exogenously is also blunted, as 
doses of EPO required to generate a response is much higher when compared to doses 
administered to patients with renal failure. 
The chief regulator of erythropoiesis is the hormone erythropoietin which acts on specific 
target cells present in the marrow with the help of cell surface receptors. From the pool of 
erythroid colony-forming cells it stimulates the production and maturation of erythroid 
progenitor cells. (19). Furthermore, erythropoietin can lead to the premature release of cells, 
as well as reticulocytes, from the marrow.  This may be counterbalanced by death signals, 
leading to impaired RBC production. In this context, it was seen that increased apoptosis of 
bone marrow erythroid precursors was demonstrated in sepsis patients. .  
Anemia and hypoxia are the key stimulators of erythropoietin release. In the acute and 
chronic phases of anemia, the erythropoietin levels in the plasma are inversely related to 
plasma Hb levels.  
In critically-ill patient presenting with long standing conditions like rheumatoid arthritis or 
cancer (20), the normal response to erythropoietin may be blunted , resulting in anemia. TNF 
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and IL-1, that are released  during sepsis, surgery, certain infections and trauma, have been 
related to a decrease in the erythropoietin production, and this may also affect the 
erythropoietin receptor (21), hence affecting the release and function of erythropoietin.  
Sufficient supplies of iron, vitamin B12 and folic acid are necessary for the normal 
erythrocyte development and a deficiency of any of these elements can lead to anemia.(22). 
Presence of increased oxidative stress, which occur in conditions like sepsis can also 
decrease the formation of EPO and inhibit erythroid precursor cells.  
Iron deficiency can also result due to haemorrhage or repeated phlebotomy. Also, some ICU 
patients have nutritional deficiencies related with the present disease condition. These, 
however, are not likely to be the chief source of anemia in the ICU patient. 
A number of drugs can also affect the production of RBCs like nitrous oxide, which causes 
megaloblastic changes thus limiting bone-marrow DNA synthesis. 
 Reduced iron availability 
Hepcidin, the key regulator of iron metabolism acts by binding to the iron exporter 
ferroportin, thereby causing internalization of iron and inhibiting the release of iron from 
tissue macrophages. Thus, hepcidin reduces the concentration of iron in the blood. Its 
production is up regulated in response to increased serum iron levels.  
Inflammation also induces hepcidin, which acts fast resulting in a drop in iron levels within 
hours (23)(11). Studies have shown that infusion of IL-6 into human volunteers induces 
increased hepcidin synthesis with a decrease in plasma iron levels (24). 
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Hepcidin levels are elevated in critically ill trauma patients, correlating with the duration of 
the anemia (25), and also in critically ill patients not suspected for iron deficiency. 
 Increased red blood cell clearance 
The cause for decreased RBC lifespan in inflammation is thought to be due to an altered 
morphology of the RBCs, leading to increased adherence to the endothelium following which 
they are cleared from the circulation. The various mechanisms responsible for erythrocyte 
clearance in physiologic senescence and inflammation are: 
 Phosphatidylserine (PS) exposure,  
 Erythrocyte phagocytosis 
 Reduced deformability  and  
 Adherence to endothelium.(10) 
Sphingomyelinase is an enzyme which converts sphingomyelin into ceramide (26). Ceramide 
enhances the sensitivity of RBCs to raised intracellular Ca2+ concentration, and hence 
enhances PS exposure. A number of factors can lead to an increase in the  plasma levels of 
sphingomyelinase, and some of these are also seen in sepsis, such as tumor necrosis factor-
alpha  and platelet activating factor (PAF) (27). 
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Moreover, bacteria such as Staphylococcus aureus also produces sphingomyelinase (28) 
which can convert sphingomyelin into ceramide . Ceramide thus enhances PS exposure 
which causes accelerated RBC clearance during inflammation.  
Numerous factors decrease RBC deformability during sepsis like Reactive oxygen species 
(ROS) which causes RBC deformability in inflammation. ROS leads to protein degradation 
in RBCs in vitro (29), particularly of  membrane proteins namely band 3 and spectrin.  
NO is a mediator which acts as a vasodilator and is released by the vascular endothelial cells 
(30). Small amounts of NO is present in the blood under physiological conditions, but during 
inflammation and infection the concentration increases by 10-fold. NO also causes a decrease 
in the RBC deformability. 
Another implicated factor in the clearance of RBCs during inflammation are sialic acid 
residues (SA) that are bound to glycophorin and is the reason for the negative charge of the 
RBC membrane (31). Due to this negative charge, RBCs manifest repellent property. SA 
content was reduced in the RBCs from critically ill patients when compared to RBCs from 
healthy volunteers. This was also associated with a decrease in RBC deformability. 
Treatment of anemia 
Therapy for anemia in the ICU was always directed to correcting the hemoglobin to an 
arbitrary “normal” because of the professed risk of anemia leading to increased morbidity 
and mortality.  
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The different modes of treatment of anemia in the ICUs are:  
1) Blood transfusions 
2) Erythropoietic agents 
3) Iron therapy 
4) Blood substitutes 
Erythropoietic agents 
Erythropoietic agents are used in critically ill patients in an attempt to reduce the need for 
blood transfusions. The rationale for recombinant erythropoietin (rHuEPO) therapy is that an 
increase in erythropoiesis results in higher Hb levels, thus reducing the need for RBC 
transfusions. This was confirmed by early experimental studies which demonstrated that 
rHuEPO when given in the perioperative period accelerated erythropoiesis resulting in 
drastically shorter times for haemoglobin to reach baseline levels. (32),(33) 
In a study, long term treatment with a weekly dose of rHuEPO considerably reduces the 
exposure to RBC transfusions during the first 42 days of rHuEPO therapy. These patients 
achieved a higher hemoglobin level in spite of fewer packed cell transfusions.(34).The 
disadvantage of rHuEPO was that it was associated with an increased incidence of 
thrombosis. 
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Iron therapy 
Iron therapy has a role for a subgroup of critically ill patients who have both anemia of 
inflammation (AI) and iron deficiency anemia (IDA). Patients are considered to have both 
IDA and AI if they have decreased hepcidin and serum transferrin/log ferritin ratios along 
with elevated CRP and ferritin levels. The tests available to discriminate the two are 
currently not available. Iron causes oxidative stress thereby increasing the risk of bacterial 
infection. Absorption of oral iron may be reduced in patients with AI due of the effect of 
hepcidin mediated decrease of ferroportin in duodenal enterocytes. Iron has to be  
supplemented in patients on erythropoietic agents for a favorable response.(1) 
Blood substitutes  
These are synthetic products that have oxygen-carrying capacity. Red cell substitutes include 
haemoglobin based oxygen carriers (HBOC), per fluorocarbon emulsions and liposome 
encapsulated haemoglobin.  
The various modifications of HBOC s are unmodified cell-free haemoglobin, cross linked 
haemoglobin, polymerised haemoglobin and surface- conjugated HBOCs. All of them have 
longer shelf life with permissive storage conditions.  There is no need for compatibility 
testing, and due to pathogen inactivation, there is absence of infectious risks. Majority of the 
oxygen carriers under development are based on either human or bovine hemoglobin.  
Outdated RBCs are the source of human hemoglobin. They have increased oxygen carrying 
capacity, exert considerable oncotic properties thereby increasing the blood volume by an 
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amount which is greater than the transfused volume. They also have vasopressor effects due 
to the scavenging effects of nitrous oxide (35). 
Blood transfusions 
Blood transfusions are used in critically ill anemic patients to improve the oxygen delivery to 
tissues. Studies have shown that more than 50% of patients admitted to the ICU receive 
blood transfusions, the number increasing to 85% in those with longer length of stay ( greater 
than seven days) (8) 
Transfusion triggers 
The historical and empirical „10/30 rule‟ was used for many years with regard to the 
transfusion practice. In 1942, Adams and Lundy initially recommended this as one amongst 
several perioperative suggestions to improve the result of surgical patients who have poor 
post anaesthetic outcome [8]. However, this rule has been misinterpreted and used roughly. 
Many years later, the term „transfusion trigger‟ came into existence. This term referred to a 
critical level of Hb level below which packed cell transfusions should be initiated.  
Weiskopf et al (35) found that in the resting state,healthy individuals are able to  withstand 
an state of acute state of  isovolemic haemodilution uptil a drop of Hb to 5 g/dl, despite the 
fact that some amount of reduction in the mental functions may be present at this level of Hb. 
It was studied that in these individuals at rest, there was no considerable change in the 
venous oxygen saturation or the lactate concentration within the plasma even though the 
transport of oxygen was reduced throughout the phase of haemodilution (using 5% albumin 
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or plasma) uptil Hb dropped to 5 g/dl. However, the critical level of Hb increases in the 
presence of coronary artery disease. 
In animal models, when 75% coronary artery stenosis was present, cardiac dysfunction was 
seen at a Hb level of 7 g/dl [24]. By challenging normovolemic anemic subjects or by 
measuring parameters of cardiovascular/cardiorespiratory function, (38) the consequences of 
oxygen deficit was seen at hemoglobin levels between 5 and 6 g/dL. These deficits were 
recoverable following the reinfusion of  red cells.  
A randomized controlled trial of 7 vs. 10 g/dL Hb thresholds in critically-ill patients, as well 
as  patients with atherosclerotic disease , showed that  lower threshold considerably reduced 
overall morbidity and mortality and it was not related to prolonged length of stay or 
morbidity in patients with cardiovascular disease, nor prolonged amount of ventilation for 
those requiring a respirator (39).  
The authors concluded that a threshold of 7 g/dL Hb was apt across all critically-ill patients 
with the exception of those with unstable cardiac conditions in whom there was a statistically 
nonsignificant trend toward increased mortality when a more restrictive threshold was used. 
Transfusion is not normally indicated if anemia has persisted for weeks or months, as  
counter active mechanisms have had time to work. These anemias are best treated by 
addressing their etiologies, such as nutritional deficiency (e.g., iron) or by reducing the speed 
of autoimmune hemolysis. Any of these situations might necessitate a transfusion if the 
patient symptomatically requires a more rapid reversal than which may be achieved by 
correcting the underlying etiologies. 
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Clinical studies – towards finding a critical transfusion threshold 
Retrospective analysis of medical and surgical patients belonging to Jehovah‟s Witness (40) 
recognized fifty deaths, of which twenty three of them were as a result of anemia. Apart from 
three patients who succumbed to their illness following a cardiac surgery, all the other 
patients who died owing to anemia had Hb levels of 5 g/dl or less. In spite of this, even when 
the Hb levels decreased to 5 g/dl or less, twenty five patients survived.  
Another study comprising of 4470 critically-ill patients, those who presented with a  
cardiovascular disease showed a drift towards increased mortality as Hb levels decreased to 
below 9.5 g/dl (55% vs. 42%; P=0.09).  
Wu et al. (41) studied that older patients with acute ischemic heart disease and who presented 
with decreased admission haematocrit showed greater 30-day mortality rates. They also 
document a short term survival advantage (as measured by a lower 30 day mortality rate ) in 
patients who have received transfusions for haematocrits below 30-33%. 
In a study by Carson et al. [53] analyzing the role of transfusions in an orthopedic setting of 
8787 geriatric patients with hip fracture repair, the postsurgical transfusion did not influence 
the 30 and 90-day mortality in patients with Hb levels of 8.0 g/dl or higher, after adjusting 
for the critical Hb level, cardiac status and other risk factors, neither was there an impact of 
the  preoperatively transfusion on the  30-day mortality in patients with Hb levels of 8.0 g/dl 
or higher, signifying that this might be  a safe threshold in this subset of patients. 
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Hebert et al assessed (42) the 30-day mortality in 838 euvolemic ICU patients. In this study 
patients with Hb levels less than 9 g/dl were randomized to either a liberal or a restrictive 
arm. The 418 patients who were randomized to a restrictive arm had their Hb levels 
maintained between 7.0- 9.0 g/dl, and red cells were transfused only when Hb levels fell 
below 7.0 g/dl.  Those assigned to the liberal arm were the remaining 420 and Hb was 
maintained between 10.0 -12.0 g/dl, and transfusions were initiated when Hb levels fell 
below 10.0 g/dl.  Analysis of the results showed that the hospital mortality rate was 
significantly lower in the restrictive group than the liberal group (22.2% vs. 28.1%; P =0.05).  
In the subset analyses, 30-day mortality rates were considerably decreased in patients who 
belonged to the restrictive arm who were younger and less acutely sick. In patients less than 
55 years of age, the mortality rates were 5.7% and 13.0% in the restrictive and liberal arms, 
respectively, and in those with APACHE II scores of 20 or less, 30-day mortality rates were 
8.7% and 16.1% , suggesting that in these subgroup of patients, a more restrictive transfusion 
strategy ought to be used. 
Thus the choice to start packed cell transfusion is best guided by the patients‟ physiological 
want. However, the edge for treatment continues to be a debate and depends essentially on a 
combination of clinical signs and symptoms at the patients side in conjunction with 
laboratory data and available measures that best denotes variation in tissue oxygenation. 
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Drawbacks of transfusion: 
RBC transfusions are used in the intensive care setting to increase oxygen delivery and 
improve tissue oxygenation. Hypothetically, an increase in Hb concentration increases the 
oxygen-carrying capacity of blood and delivering more oxygen to the tissues. However 
increasing evidence question the efficacy of RBC transfusion at improving outcomes in 
clinical situations other than acute haemorrhage. 
Some of the non infectious and infectious hazards of transfusion are as follows: 
       1.   Transfusion reactions 
       2.   Transfusion related immunomodulation 
       3.   Transfusion transmissible infections 
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TRANSFUSION REACTIONS 
 
Fig 2 FNHTR-Febrile nonhemolytic transfusion reactions, AHTR-Acute hemolytic 
transfusion reactions, DHTR-Delayed hemolytic transfusion reactions, TRALI-Transfusion 
related acute lung injury, TA GVHD-Transfusion associated graft vs. host disease, PTP-Post 
transfusion purpura, TACO- Transfusion associated cardiac overload, TTI-Transfusion 
transmitted infections 
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HEMOLYTIC TRANSFUSION REACTIONS 
Hemolytic transfusion reactions can be classified as acute or delayed reactions. 
Acute hemolytic reactions can be defined as those reactions that occur within 24 hours of 
blood transfusion. They can be due to the presence of preexisting recipient alloantibodies 
against antigens on the donor erythrocytes. Mostly, the offending antibodies are 
immunoglobulin IgM which are naturally occurring like anti-A or anti-B), although 
complement fixing IgG alloantibodies could  also be responsible. 
 The incidence of acute hemolytic transfusion reactions is estimated  to be 1 in 40,000 
transfused blood components (43). Immune-mediated hemolytic reactions, rarely can occur 
because of RBC antibodies in the plasma of the transfused product. 
Delayed hemolytic transfusion reactions (DHTRs) usually occur between 24 hours and 1 
week following the transfusion of apparently cross-match compatible RBCs. In these 
situations, the recipient has been previously sensitized to RBC antigens, either through 
pregnancy or transfusion. These alloantibodies which are usually IgG isotype typically 
against Rh and Kidd system and are present in such low levels that they are not detected 
during the pretransfusion antibody screen. However, following transfusion, there is a rapid 
anamnestic response leading to hemolysis. It has been estimated that DHTRs occur in 
approximately 1 in 7000 transfusions (43). 
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Fig 3. Complement activation during Hemolytic Transfusion Reactions. Stowel et al 
(44) 
RBC ALLOIMMUNIZATION 
It has been found that approximately 2%–8% of patients who are chronically transfused 
develop RBC alloantibodies(45). Contrary to other minor RBC antigens, the percentage of 
patients exposed to RhD who will develop an anti-D antibody is approximately between 30% 
and 80%. In the presence of RBC alloantibodies, locating compatible, antigen-negative RBCs 
are complex and moreover they may increase the risk of a delayed hemolytic transfusion 
reaction. 
Rates of alloimmunization vary with the disease status such as sickle cell anemia patients in 
whom rates of alloimmunization are approximately 40%(46).  In a recent study in China 
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done among chronically transfused thalassemia patients, rates of  alloimmunization was 
found to be as high as 23% (47). 
FEBRILE NONHEMOLYTIC TRANSFUSION REACTIONS 
FNHTRs have been characteristically defined as a 1°C increase in temperature during or 
soon after commencement of a transfusion. Associated symptoms include chills, rigors, and 
discomfort. It is usually seen after platelet transfusions than RBC transfusions. The incidence 
rates ranges from 1% to <35%.  
One mechanism is the interaction that occurs between the recipient‟s cytotoxic antibodies 
and HLA or WBC-specific antigens present on donor WBCs. This leads to the formation of 
antigen-antibody complexes in turn leading to complement binding with release of 
endogenous toxins. Different biological response modifiers including cytokines also has a 
role to play in these reactions. Another mechanism is mainly concerned with the storage of 
platelets which involves the continued production and release of cytokines from the  residual 
WBCs present in the product (48).  
It has been estimated that the risk of FNHTR is approximately 1 in 300 transfusions (45). 
ALLERGIC REACTIONS: 
Generalized pruritis and urticarial reactions are frequent, occurring in approximately 1–3% of 
all transfusions. They can be due to the presence of soluble antigens in the donor plasma 
which can produce a dose-dependent clinical response. 
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Allergic reactions occur in approximately 1 in 100 transfusions and anaphylactic reactions 
can be seen in approximately1 in 40,000 transfusions. (45). 
IgE mediated reaction against protein hapten conjugates and complement mediated 
production of anaphylotoxins are the two projected mechanisms responsible for 
anaphylactoid reactions. 
TRALI (TRANSFUSION RELATED ACUTE LUNG INJURY) 
The incidence of TRALI is estimated to be 1 in 5000-10,000 red cell transfusions (45).  
 Fresh Frozen Plasma was the most commonly implicated product. According to The United 
Kingdom‟s Serious Hazards of Transfusion (SHOT) hemovigilance data, the risk of TRALI 
per component was 6.9 times higher for FFP than for RBCs.  
TRALI is characterized by acute hypoxemia with non cardiogenic pulmonary edema that 
occurs during or within six hours of commencement of a transfusion.(49) Majority of patients 
usually recover in three days with the help of respiratory support, but approximately 5% to 
25% of cases can be fatal.  
The primary mechanism involved in the causation of TRALI is the accumulation and 
activation of neutrophils within the pulmonary endothelium. A two hit hypothesis has been 
proposed for TRALI. The first hit is a recipient factor that primes neutrophils on the 
pulmonary vasculature and the second hit is a mediator present in the transfused component 
which activates the primed neutrophils and causes increased permeability of the vascular 
endothelium.   
32 
 
Recipient factors includes a variety of factors like pre transfusion fluid balance, mechanical 
ventilation, patient in shock, following liver transplant surgery, IL-8 concentration pre-
transfusion, end-stage liver disease, hematologic malignancy, sepsis etc. Antibodies that are 
present in donor plasma, when transfused to a patient who has the related antigen stimulates 
neutrophils within the pulmonary vascular endothelium which agglutinate and thereafter  
release enzymes, ROS, and inflammatory mediators that will injure the pulmonary 
microvasculature.(50),(51) 
HLA Class II antibodies are most often the culprits than Class I antibodies and can indirectly 
activate primed neutrophils through monocyte activation and cytokine release. Human 
Neutrophil Antibodies, especially HNA 3a, are also known to be potent mediators of TRALI.  
A nonimmune mediated mechanism for TRALI has also been postulated in which bioactive 
substances like lysophosphatidylcholine, nonpolar lipids and CD40 ligand accumulate in the 
blood products during storage and can act as the second hit to stimulate injury in the primed 
patients.(52)(53) 
TACO (TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD) 
TACO can be defined as acute respiratory distress causing hypoxia, and pulmonary edema 
temporally associated with the transfusion of packed cells. 
The incidence is has been estimated to be approximately 1 in 700 red cell transfusions.(45) 
TACO was found to be the second leading cause of mortality in the United States in 2010, 
following which its frequency has increased significantly over the years. Although TACO 
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has been reported after the transfusion of even a single unit of RBC, increased number of 
transfusions have been implicated as a risk factor independent of the cardiovascular status of 
the patient. The most common cause of TACO is the transfusion of a unit at a much faster 
rate. Hypervolemia associated with transfusion leads to congestive cardiac failure and 
pulmonary edema. 
METABOLIC COMPLICATIONS 
A number of metabolic complications can occur when blood products are transfused.  
These complications are manly seen in neonatal patients or in circumstances wherein rapid, 
large-volume infusions occur. Such metabolic complications include effects of citrate 
toxicity, hyperkalemia, and hypothermia. 
Citrate toxicity 
The anticoagulant used during blood collection is sodium citrate. The final citrate 
concentration in blood components is found to be highest in the plasma products. Normally 
the liver rapidly metabolizes transfused citrate but during massive transfusion, the capacity of 
the liver to clear the citrate has been exceeded following which the citrate forms a complex 
with calcium, decreasing the ionized calcium resulting in a hypocalcemic state.  
Hyperkalemia 
When red cell products are stored, potassium leaks from the stored blood causing an increase 
in the concentration of potassium especially in the context of massive transfusion. 
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Studies have shown that there is an increase of roughly 1meq/day of extracellular potassium 
during the first 3 weeks of RBC storage in citrate phosphate dextrose adenine 1 (CPDA-1).  
The potassium levels of units stored in additive solutions like Adsol are higher on Day 7 than 
on Day 0 (17 mmol/L and 1.6 mmol/L respectively).  
Hypothermia 
The rapid infusion of red cell and plasma products that are stored at cold temperatures may 
lead to hypothermia, especially in patients with major trauma who may already be vulnerable 
to hypothermia, depending on the nature and extent of their injuries. 
A number of metabolic impairments occur due to hypothermia including a decrease in the 
rate of citrate and lactate metabolism, increased oxygen affinity of hemoglobin, and 
increased potassium release from the red cells. The cardiac functions are also affected due to 
reduced core body temperature leading to morbidity and mortality. Hypothermia can be 
minimized by warming the blood products before transfusion with the help of a blood 
warmer.(54),(55) 
TRANSFUSION ASSOCIATED GRAFT VS HOST DISEASE ( TA-GVHD) 
Transfusion-associated graft versus host disease occurs when immunocompetent allogeneic 
lymphocytes present in the transfused component engraft, proliferate and mount an immune 
response against the recipient tissues. 
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TA-GvHD usually occurs between 4 and 30 days following transfusion. The syndrome when 
it is full blown is associated with multiple organ system involvement leading to increased 
mortality approaching to almost 90%. TA-GvHD occurs in patients in whom the 
immunological system is not fully developed, such as following intrauterine transfusion, in 
premature infants following exchange transfusion and in immunocompromised patients. 
TA-GvHD can occur when a donor who is homozygous at the HLA loci shares one of the 
HLA haplotypes of the patient. This has been reported in Japan in patients undergoing 
cardiac surgery probably due to the use of fresh blood from directed donations in  
populations having a high HLA homology.  
The donor T lymphocytes are inactivated by irradiation to prevent GvHD resulting due to 
blood transfusion.. T-cell responses are undetectable after the exposure to at least 25 Gy.(56) 
POST TRANSFUSION PURPURA 
Post transfusion purpura is an  infrequent complication characterized by purpura, epistaxis, 
gastrointestinal bleeding, and thrombocytopenia, classically seen 5–10 days following 
transfusion. It is presumed to result from antiplatelet antibodies most commonly against HPA 
1a that reacts with the transfused platelets resulting in the formation of immune complexes or 
the release of complexes that are released after destruction of donor platelets.  
In both these cases, the immune complexes adhere to the patient‟s platelets following which 
the platelets are sequestered. Glycoprotein GPIIb (HPA-3a, HPA-3b) and GPIIIa (HPA-1a, 
HPA-1b; HPA-4a) are the more commonly implicated platelet antigens.  
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In addition to anti-HPA-1a, another mechanism of secondary immune response, is the 
formation of  cross-reactive antibodies against a common epitope common that is common to 
both to HPA-1a and -1b (57) 
BACTERIAL CONTAMINATION 
Sepsis related to the transfusion of bacterially contaminated red blood cells is also an 
uncommon event incidence rate being 1 in 50,000 (43) ,with fatality rate of 1 in 104,000 
transfused RBC units.  It has been found at the time of phlebotomy itself, one in 2000 units 
of blood may be contaminated from skin. 
The most commonly implicated endotoxins are those produced by bacteria capable of 
growing in cold temperatures such as Pseudomonas species, Escherichia Coli ,  Yersinia 
enterocolitica,  Serratia marcesans and Aeromonas species . They grow very slowly in cold 
blood, dividing about once a day, taking approximately 27 days to grow up to 10
8
 organisms, 
hence resulting in an overwhelming infection and septic shock. (58)  
Signs and symptoms of septic reactions typically appear rapidly during transfusion or within 
30 minutes following transfusion.  
RBC STORAGE DEFECTS  
Storage of RBCs for long periods can also be responsible for the deleterious effects of 
transfusion. Metabolic, biochemical and molecular changes can be seen in RBCs stored over 
a 42 day period.  
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Membrane changes 
RBCs undergo glycolytic metabolism secondary to which there is accumulation of lactic acid 
and H
+ 
over time. Secondary to this however, the pH in the blood bag drops , altering 
glycolysis, leading to a rapid decline in 2,3 DPG levels and a rapid increase in ATP 
production. Following this the rate of glycolysis is seen to decrease, and ATP production 
likewise due to accumulation of acid. By the 10
th
 day of storage, 2, 3 DPG decreases 
drastically while ATP concentrations increase during the initial days or remain stable for the 
first two to four weeks. Thereafter a decline is noted.  
RBCs collected in CPDA- 1 show decreasing levels of RBC ATP content on storage. Studies 
show a decline from  4.18mmol/g Hb at collection to 2.40mmol/g Hb at 35 days of storage. 
Consequentially, red cell shape is affected by both  acidification and lowering ATP 
concentrations  (59). Echinocytes seen are a result of acidosis which causes the initial 
development of bumps leading to surface protrusions, hence forming echinocytes. These 
initial changes are reversible. However, as calcium concentration of the RBC increases and 
RBC ATP decreases, irreversible changes begin to set in. The changes include asymmetry of 
the phospholipid membrane being lost, the development of phospholipid rafts which are 
negatively charged on the surface of the cell, and the microvesicle formation   The results of 
these changes is that with storage of red cells there is permanent membrane loss. With 
storage and over time it has also been noted that the rigidity of RBCs increases and they tend 
to become  more adherent to vascular endothelium.(60),(61) 
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Fig 4.   Electron microscopic pictures of RBCs showing the morphological changes from 
biconcave disc shaped to microspherocytes occurring as a result of storage for 42 
days(62) 
CD47, is a 50-kd  glycoprotein, which is expressed on the surface and transmembrane in 
location. Widely expressed on all cells, it has been found that its expression decreases by 10–
65% on RBCs when stored. It is used as a marker for self and therefore when expression falls 
to less than 50%, these red cells become susceptible for phagocytosis. It has been observed 
that approximately 20–25%  of  red cells are non viable at the end of the storage time and 
when transfused then  are removed within a few hours from the circulation.(58) 
In red cell products which are not leukocyte reduced, two weeks after storage Phosphatidyl 
serine (PS) becomes expressed. This sets off a procoagulant effect contributed by the 
inherent risk of increased adherence of these cells to vascular endothelium. This  further 
result in compromise of blood flow, resulting in impaired oxygen delivery, and 
vasoocclusion of microvasculature in vivo. Situations  in patients  with high oxygen demands  
and  impaired micro vascular perfusion should specifically take these changes into 
consideration.(63) 
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Inflammatory mediators like histamine, complements, lipids and cytokines accumulate in the 
supernatant of leukocyte containing RBCs.  After storage for two weeks, there is increased 
expression of CD11b and CD16 on neutrophils in vitro, both of which are related to the 
priming of neutrophils. (64) 
During red cell storage, residual platelets and red cells release factors like the CD40Ligand 
which is proinflammatory in nature and other lipid peroxidases which can be bioactive, 
respectively. These are capable of priming polymorph nuclear cells (PMN) and have been 
purported to be cofactors causing TRALI. (60) 
2, 3-DPG 
 2,3-DPG is gradually depleted in the two week stored RBC leading to a  shift of the O2-
dissociation curve to the left thereby increasing oxygen affinity and impairing its delivery 
(65). There is considerable variability in the rate of in vivo restoration of 2, 3-DPG. One hour 
after transfusion, 25–30% of 2,3-DPG has been measured , after 24 hours there was 50% 
recovery but a full restoration was seen only after three days (63). 
Sodium Potassium Pump 
The Na+ ⁄ K+ pump is paralyzed at storage at 2-6°C when K+ leaves the cell and sodium 
enters the cell [36]. Following 3 days storage there is progressive leakage of potassium from 
the erythrocyte and the extra-cellular concentration can increase to 50 mEq ⁄ l. 
Following transfusion, the red cell sodium content normalizes within 24 h, but it takes at 
least 4 days for complete K+ recovery [37]. High potassium levels is associated with the 
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danger of arrhythmias which is mainly seen with large volume transfusions in newborns and 
small infants, in whom lethal cardiac arrest have been reported (6).  
Clinical trials based on storage of RBCs vs. mortality and lengths of ICU stay 
It was reported in a study by Purdy et al, in a population of 31 transfused septic patients, a 
significantly longer mean storage time of transfused RBCs was seen in patients who died (25 
days) when compared to those who survived (17 days),P <0.0001. (66) 
Eikelboom et al (67) reported an independent association between the risk of  hospital 
mortality and prolonged storage of red cells in patients with cardiovascular disease. 
Similar association was seen between RBC storage time and ICU length of stay by Martin et 
al in 698 ICU patients. It was noted that the transfusion of RBCs stored for more than 14 
days was independently associated with prolonged ICU length of stay. 
A study by Murrell et al in trauma patients reported a statistically significant association 
between ICU length of stay and the dose of aged blood (defined as the average age of 
received RBC multiplied by the number of RBC received). 
The duration of red blood cell (RBC) storage before transfusion alters RBC function and, 
leading to complications or even mortality, but this still remains a matter of debate. Lelubre 
and Vincent in a systematic study review found  no definitive argument that was able to 
support the superiority of fresh RBCs over older RBCs.(68) 
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TRANSFUSION TRANSMITTED INFECTIONS 
Transfusion transmitted disease (TTD) has been a major challenge in the field of transfusion 
medicine. In the blood donor community, the problem of TTD is directly proportional to its 
prevalence. Some of the main infections that are of concern in India include hepatitis B/C, 
HIV, malaria, syphilis, cytomegalovirus, parvo-virus B-19 and bacterial infections. 
There is a 1% chance of transfusion associated problems including TTI with every unit of 
blood. In India, the overall prevalence of TTI is 0.6%. Data obtained from various studies on 
the overall seroprevalence of HIV, HBsAg, HCV and Syphilis in India were 0.44, 1.27, 0.23 
and 0.28% respectively.(69) 
Hepatitis B and C infections are prevalent in India and carrier rate is about 1-5% and 1%, 
respectively. Post transfusion hepatitis B/C has also been a major problem in India (about 
10%) due to low viraemia and the presence of a mutant strain that is undetectable by routine 
ELISA. 
A study done by Ali et al. showed post transfusion malaria incidence of 4.9% for multi-
transfused patients. In another study the overall malaria antigen prevalence in blood donors 
was 0.09% and the malaria antibody prevalence was 6% in thalassemia patients and 15% in 
other multi transfused patients.(70) 
The prevalence of anti CMV IgG in India is about 95%. Studies have found that about 5% of 
the donor population have IgM antibody which carries a considerable threat of transmitting 
CMV infection when transfused to the immune-compromised population. It is very difficult 
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to prevent post transfusion CMV but with the use of leukocyte filters, its incidence has 
reduced significantly.   
Prevalence of parvo virus B-19 infection in blood donors is 39.9% which may contribute to 
increased morbidity when transfused to multitransfused or immunocompromised 
patients.(71) 
Another emerging infection, i.e. chikungunya virus (CHIKV), has been a threat to the South 
Asian countries. Transfusion associated CHIKV is a problem during outbreaks and the high-
titer viremia lasts for up to 6 days. During its outbreak, the estimated transfusion risk is about 
150 per 10,000 transfusions. (68) 
TRANSFUSION RELATED IMMUNOMODULATION 
Allogeneic blood transfusion results in either alloimmunization  or immune tolerance. 
Laboratory studies to demonstrate  the effects of allogeneic transfusion on  immunological 
function, have demonstrated reduced interleukin2 (IL-2) secretion, reduced natural killer cell 
activity, reduced delayed-type hypersensitivity responses with decreased CD4/CD8 ratios 
(72),(73) and decreased function of macrophages. 
This was found to contribute to tumor recurrence, augmented rates of infections, rapid 
progression of viral diseases, and a decrease in the inflammatory bowel disease episodes. 
The concept about immunomodulation came into existence when Opelz et al.in 1973 found 
better outcomes among recipients of cadaveric renal transplants who had received packed 
cell transfusions. This phenomena was recognized to be due to the immunomodulatory effect 
43 
 
of the transfused leukocytes, alterations in the circulating lymphocytes, function of Bcells, T 
helper cell /suppressor cell ratio and the number of circulating antigen presenting cells(APC) 
in the recipients of allogeneic blood transfusion. (74) 
Thereafter, it was postulated that there may be two categories of immunosuppressive 
transfusion effect: one that is HLA dependent which is directed against the adaptive 
immunity and another non-specific effect which is against the innate immunity.  
The nonspecific effect was presumed to be due to the transfusion of blood cells that undergo 
apoptosis during storage under refrigerated conditions. This immunosuppression following 
the transfusion of these cells may be attributed to the transforming growth factor beta (TGF-
β). 
With the transfusion of large amounts of fresh or stored blood, changes can be seen in the 
recipient‟s lymphocytes after a period of about 1 week.  It was reported that atypical 
lymphocytes was seen to increase by a factor of five or more.  
It is purported that TRIM may be due to any of the following: 
• Allogeneic mononuclear cells (AMCs) present in blood stored for less than 2 weeks 
• Pro-inflammatory soluble factors that are released from WBC granules which accumulate 
progressively in the supernatant of stored RBCs. 
• Soluble, class I HLA molecules that circulate in the allogeneic plasma. 
44 
 
LANDMARK STUDIES FOCUSSING ON ANEMIA AND RED CELL 
TRANSFUSION IN THE INTENSIVE CARE UNIT. 
In the ICU, transfusion must be viewed as any other intervention as it is associated with 
definite risks. The expected benefits and risks should be rightly weighed in the light of the 
goal of transfusion.  
Several landmark studies have explored transfusion thresholds in critically ill patients and 
have evaluated the factors associated with the need for transfusion and the relationship 
between transfusions and outcomes. 
CRIT Study (75) - A prospective multiple centre observational study was done in the United 
States which included 213 hospitals consisting of 284 ICUs. It was a nine month study period 
and 4,892 patients were enrolled.  
In this study the mean baseline Hb on admission to ICU was 11g/dl, which significantly 
decreased to 9.8g/dl by the end of the study. Almost 70% of the patients admitted to the ICU 
had baseline haemoglobin less than 12g/dl by 48hrs after ICU admission, and half of these 
patients had a haemoglobin level of less than 10g/dl. It was seen that all through the duration 
of ICU and hospital stay, the anemia persisted regardless of the presence or absence of RBC 
transfusion. Individuals who had lower baseline haemoglobin were prone to receive an RBC 
transfusion. Almost 90% of patients with a baseline haemoglobin of less than 8g/dl received 
packed cell transfusion. On the contrary, merely 20% of patients with baseline haemoglobin 
more than 12g/dl received packed cell transfusion. Patients with a low haemoglobin level less 
than 8g/dl presented with more hemodynamic instability, sepsis and GI bleeding whereas 
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patients with a haemoglobin level greater than 12g/dl presented with more respiratory and 
cardiovascular problems. ICU or hospital length of stay was not statistically significantly 
associated with baseline haemoglobin. 
44% of the ICU patients received transfusion of one or more than one RBC units while in the 
ICU with the average time to first transfusion being 2.3±3.7 days. More number of packed 
cells was transfused in the first week, when compared to the following weeks when patients 
received 1-2 RBC units per week. When compared to patients who had a shorter stay in the 
ICU those with a longer stay of seven or more days received transfusions more commonly 
(33.4% vs. 63%). The mean number of RBC units transfused was 4.6units.  
Transfusion of packed cells was also independently associated with rates of mortality. It 
continued to be statistically significantly associated with an increased risk of death following 
adjustment for the propensity for receiving a transfusion, (adj OR-1.65, p<0.001). 
Transfused patients had more complications and were also more likely to experience a 
complication. Those who received six or more RBC units had greater mortality rates than 
those who received no transfusions at all (25%vs10%). The number of units that were 
transfused was statistically significantly associated with prolonged ICU and hospital length 
of stay when compared to patients who had not received any transfusions. 
The mean pretransfusion haemoglobin was 8.6g/dl and the indication for transfusions were 
primarily low haemoglobin in majority of the cases (90%), followed by active bleeding 
(24%), presence of ischemia (3%), increased cardiac output(2%), prior to or after a surgical 
procedure(19%) and hypotension(21%).  
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Mean baseline APACHE II score was 19.7±8.2 and this was significantly greater in those 
with baseline haemoglobin less than 10g/dl. Lower baseline APACHE II was found to be 
associated with a significantly decreased probability of RBC transfusion.  
The average age of transfused RBC units was 21.2±11.4 days. No difference was seen in the 
clinical outcome and the average age of units that a patient received.  
Anemia and Blood Transfusion in Critical Care (ABC)
 
(9) study examined the incidence 
of anemia and use of transfusions in critically-ill patients. The study was a prospective, 
observational study including 146 Western European ICUs and consisting of 3534 patients.  
In the study, the mean age of patients was 61years with 33.4% of patients being older than 
70years.  
The mean admitting haemoglobin was 11.3g/dl with mean admitting APACHE II score 
of14.8 and mean SOFA (Sequential Organ Failure Assessment Score) of 5.5. 
 Lower mean haemoglobin levels were associated with higher SOFA score, longer lengths of 
ICU and hospital stay and higher mortality rates. 
 The rate of RBC transfusions during ICU and post ICU period was 37% and 12.7% 
respectively. Almost 70% of the transfused patients received their initial transfusion during 
the first two days in the ICU. Those patients who remained in the ICU for more than seven 
days in general had a transfusion rate of 73.3%.  
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Those who were transfused were much older with higher admitting SOFA and APACHE II 
scores, lower admission Hb levels, and prolonged length of hospital stay. 
The mean pre transfusion haemoglobin was 8.4g/dl.  The mean age of the transfused RBC 
units was 16.2 days. Mean length of ICU stay was 4.5days(less than 1day-46.6% patients, 2-
3days-21.4%, 4-7days-14.2% and more than 7days-17.8%). When the transfused groups 
were compared, the average number of ICU days was 7.2days for those who received 
transfusions when compared to 2.6 days for those who had not received any transfusion.  
The overall ICU mortality was 13.5%. And it was found to be significantly higher for the 
transfused vs. non transfused patients (18.5% vs. 10.1%). Logistic regression showed a 
significant association between transfusion, APACHE II score, SOFA score, and age with 
mortality but such an association was not seen with the admission Hb. 
There was a dose response relationship with increased mortality rates as the number of RBC 
units transfused increased and it was seen that receipt of a transfusion had increased the risk 
of dying by a factor of 1.4. 
Transfusion Requirements in Critical Care (TRICC)
 
(76)
 
 Study. 
Over a three year period investigators of the TRICC study group and the Canadian Critical 
Care Trial groups had 838 patients enrolled into their study. There were 22 Canadian tertiary 
level intensive care units and 3 community level intensive care units which these patients had 
been admitted during this time. 
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The 838 patients enrolled, were assigned to either a restrictive or a liberal strategy of 
transfusion.  418 were assigned to the former, while 420 were assigned to the latter group.  
Analyzing APACHE II score revealed an average score of 21. It was also observed that 
mechanical ventilation was required for more than 80% of the patients. 
Analysis of threshold for red cell transfusion between both groups revealed some differences. 
The Hb of patients assigned to the restrictive strategy was maintained in the range of 7.0 to 
9.0 g/dl. A haemoglobin concentration below 7gm/dl was the threshold for initiating a 
transfusion. On the contrary, among patients assigned to the liberal strategy Hb levels were 
maintained at 10.0 to 12.0 g/dl, and transfusions were initiated at a threshold of 10.0 g/dl.  
Differences were observed in the mean number of red cell units transfused between these two 
groups as well. The mean number of RBC units transfused per patient in the restrictive group 
was 2.6±4.1 whereas in the group with the liberal strategy it was 5.6±5.3 units per patient.   
While differences were noted in ICU and hospital mortality rates – with rates being lower in 
the restrictive strategy group when compared  to the liberal strategy group( 22.2%vs28.1%), 
there was no difference in the 30-day mortality –values being similar in the two groups 
(18.7% vs. 23.3%, P= 0.11).  
Comparing the two groups and looking at the unadjusted odds ratio for mortality within 30 
days showed a value of 0.75 (P=0.09). Adjusting for variables such as age, APACHE II 
score, other significant diagnosis, and coexisting illnesses, there was no significant change in 
the Odds ratio.(odds ratio, 0.72; P=0.07). 
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A significant finding was the lower mortality rates in the restrictive strategy group who were 
also less acutely ill as evidenced by an APACHE score <20 (8.7% in the restrictive-strategy 
group vs. 16.1% in the liberal-strategy group, P=0.03). This was also replicated in younger 
patients – less than 55 years of age (5.7% mortality vs. 13.0% mortality, respectively; 
P=0.02). However when the patient population had cardiac disease that was of clinical 
significance, this trend did not hold (20.5%vs22.9%, respectively; P=0.69).  
This study reflected a trend that maintaining Hb levels between 7.0 to 9.0g/dl and adopting a 
restrictive strategy of transfusion practice was advantageous as it appeared to decrease 30 
day mortality and alongside also decrease mean number of red cell transfusions by almost 
54%. 
Sepsis Occurrence in Acutely Ill Patients (SOAP) Study
  
(77) – This was a multicentre, 
observational study comprising of adult patients admitted to 198 European ICUs.  
Of the 3,147 patients, 1040 patients (33%) received an RBC transfusion. Older patients 
(mean age 62years) received more transfusions and were more likely to have liver 
pathology/surgical admission/infection/sepsis.  
Comparing transfused and those not transfused in the study revealed that the transfused 
patients had a longer ICU stay (5.9vs2.5days) when compared to the non transfused with a 
higher ICU mortality rate (23%). However these patients were more acutely ill with a higher 
baseline APACHE II score (40.2) at admission than other patients. It was observed that those 
who received more transfusions also had a longer ICU stay.  Analyzing relationship between 
number of units transfused and mortality rate, there appeared to be a direct relationship. 
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However in multivariate analysis, mortality rate and receipt  of blood transfusion was not 
significantly associated  Using the  extended Cox proportional hazard analysis, adjusting for 
red cell transfusion as a time-dependent variable, it was found to be associated with a 
decreased relative hazard of death at 30 days in the entire population. 
Audit of Transfusion in Intensive Care (ATICS)Study
 
(78) – This was a prospective study 
comprising  1042 patients admitted successively to 10 Scottish adult ICUs during a 100 day 
study period. 
The admission haemoglobin was less than 9g/dl in 21% of patients and approximately 27% 
of patients developed a haemoglobin concentration of less than 9g/dl on at least one occasion 
during ICU stay.  
The percentage of patients who received RBC transfusions in the ICU was 39.5% and the 
RBC requirement in the ICU was approximately 1.87 RBC units per admission. 
Transfusion episodes due to clinically significant haemorrhage (an estimated loss around 
300ml during a 24 hour period) accounted for 40% of all transfusions with a mean of 3.1 
units per episode. Transfusion episodes not associated with clinically significant 
haemorrhage amounted to 60% of all transfusion episodes with a mean of 1.9 units per 
episode. The median transfusion threshold haemoglobin level for RBC transfusions that were 
not associated with haemorrhage was 7.8g/dl. The mean ICU length of stay was 2.2 days and 
the mean APACHE II score was 19.8. 
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MATERIALS AND METHODS 
Study Design and Settings: 
This prospective observational study was conducted in the Medical and Surgical ICU of 
Christian Medical College Hospital, Vellore. This is a 2500 bedded tertiary referral centre 
with a 12 bedded Medical ICU, 12 bedded Medical HDU and 13 bedded Surgical ICU. The 
enrollment period was from October 2012 through June 2013.The study protocol was 
approved by the Institutional Review Board.   
Study participants: A total of 800 patients were enrolled throughout the study period. 
Patients were enrolled within 48hrs of ICU admission. 
Inclusion criteria: All patients admitted to the medical and surgical ICU, with an anticipated 
stay of more than 48hrs were enrolled in the study. 
Exclusion criteria included: 
1. Patients with known primary haematological disorder 
2. Patients who succumb to their illness or are discharged within 24hrs of ICU admission. 
Patients were followed up throughout the length of their ICU stay until hospital discharge or 
if death occurred before that. 
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Data collection: 
Data was collected exclusively by the principal investigator using pre printed case report 
forms (CRF‟s) (Annexure II). All patients who met the inclusion criteria were recruited into 
the study. Data collection included demographics, primary diagnostic category, type of 
surgery(if applicable), co morbidities, admission haemoglobin and  APACHE II score. 
Follow up of these patients included daily data collection of hemoglobin, requirement of 
RBC transfusions, indication for transfusion, pre transfusion haemoglobin, number of RBCs 
transfused, ventilator days, ICU and hospital length of stay and outcome. 
The daily haemoglobin values were obtained either from the Arterial blood gas analyzers    
(Gem 4000, from Instrumentation Laboratories used  in MICU and ABL 800, Radiometer 
Copenhagen used in SICU) or from Beckman-Coulter  DXH 800 Haematology Analyzer. 
Statistical analysis:  
The study size was calculated according to the patient turnover in both the Medical and 
Surgical ICU- roughly a sample size of 1500 for a period of six months. 
The primary endpoint of the study was to evaluate the RBC transfusion practice with respect 
to transfusion thresholds and indications for transfusion in critically ill patients.  
The secondary endpoints were to determine the prevalence of anemia in ICU patients and to 
assess the time course of haemoglobin concentrations during their ICU stay. 
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A fall in haemoglobin was defined as a reduction in haemoglobin due to overt or covert 
bleed, hemolysis or due to illness per se. The fall in haemoglobin in critically ill is due to a 
multiplicity of factors that include dilutional (due to fluid resuscitation), anemia of illness, 
repeated blood tests, with or without clinical bleeding or hemolysis. 
We also analyzed the effect of anemia and transfusions on the clinical outcome, to assess if 
transfusion is an independent risk contributing to mortality in critically ill patients. 
The CRF‟s were analyzed using STATA 10 with the data base created in EXCEL. 
Descriptive statistics were computed for all data variables. Difference testing between groups 
was performed using the two sample t test and associations were checked using Chi square 
test. 
 Logistic regression was conducted to assess determinants of mortality. Adjustment was 
made for potential confounding factors including age, APACHE II score, baseline 
haemoglobin, RBC transfusion and need for ventilation.   
Repeated measures ANOVA was used to detect significant difference in the decrease in 
haemoglobin between the transfused and non transfused groups following admission to the 
ICU. 
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RESULTS 
Patients who were admitted to the Medical and Surgical ICU during the period from October 
2012 to June 2013 were included in this study.  
All those patients with a primary haematological diagnosis and those who died or were 
discharged within 24 hrs of ICU admission were excluded from the study.  
After exclusion, eight hundred patients who fulfilled the inclusion criteria were recruited in 
the study.  
 
             
                   Figure 5 . Distribution of patients in the study population 
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BASELINE CHARACTERISTICS: 
Table 1. Overall characteristics of patients in the study population 
 Mean ± 
Standard deviation(SD) 
Lower quadrant(LQ) 
Median(Mdn) / 
Upper Quadrant(UQ) 
Age, years 45.0 ± 16.8 30.0/45.0/57.0 
Gender,   
Male 467(58%)  
Female 333(42%)  
Baseline APACHE II score 18.30± 7.14 13.0/17.0/23.0 
Baseline haemoglobin level, g/dl 10.7± 2.8 8.6/10.3/12.5 
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Comparison of baseline characteristics between MICU and SICU patients 
When assessed individually, the mean age of patients admitted in MICU and SICU was not 
statistically different (Table 2). The mean APACHE II score was also not statistically 
different among the patients in both the ICUs. The average admission haemoglobin in 
patients admitted to the SICU was far lesser when compared to the medical cohort in MICU 
and the difference was statistically significant.  
The most common indication for admission to the medical ICU in the decreasing order of 
frequency was organophosphorus poisoning(13%), Acute respiratory distress 
syndrome(11%), scrub typhus(11%), acute kidney injury(11%), septic shock(10.5%) and 
DIC(9%). 
The most common admission indications in the surgical ICU were abdominal surgery(29%), 
polytrauma(24%), pelvic surgery(15%), limb ischemia(12%), obstetric emergencies(7%) and 
thoracic surgery(6%). 
The prevalence of co morbid conditions varied in both the ICUs. Diabetes and Hypertension 
were the most frequent co morbid conditions seen in 34% and 28% respectively in the MICU 
and 24% and 26% respectively in the SICU.  
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Table 2. Baseline characteristics of MICU and SICU patients 
 MICU 
(N=406) 
SICU 
(N=394) 
P value 
Age, years 44.3±17.3 45.5±16.2 0.31 
APACHE II score 18.3±6.2 18.4±7.8 0.92 
Hb at admission, g/dl 
Co morbidities (%): 
Diabetes 
Hypertension 
Ischemic heart disease 
Chronic kidney disease 
11.4±3.0 
 
(136)34% 
(114)28% 
(31)8% 
(29)7% 
9.9±2.4 
 
(94)24% 
(102)26% 
(15)4% 
(22)6% 
0.00 
 
 
Fig 6. Percentage of co morbid conditions in both ICUs. 
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Figure 7.  Admitting diagnosis in MICU 
      
Figure 8. Admitting diagnosis in SICU 
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OUTCOME OF ICU STAY 
Table 3. Overall outcome of ICU stay 
 Mean± SD LQ/Mdn/UQ 
ICU length of stay, days 7.3 ± 5.4 4.0/6.0/9.0 
Hospital length of stay, days 15.8± 11.0 9.0/13.0/20.0 
Mechanical ventilation% 81  
Ventilation duration, days 5.3± 5.7 2.0/4.0/7.0 
Mortality % 25  
Eighty one percent of patients admitted to SICU and eighty percent of patients admitted to 
MICU required ventilatory support during their ICU stay and the duration of ventilation was 
significantly different in both the groups. Mortality rates and ICU length of days were 
significantly higher for the medical cohort when compared to the surgical cohort (Table 4). 
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Table 4. Comparison of outcome among the ICUs 
 
 
MICU 
(N=406 
SICU 
(N=394) 
P value 
Ventilation duration, days 6.9±6.7 3.6±3.8 0.00 
ICU length of stay, days 9.0±6.0 5.5±3.9 0.00 
Hospital length of stay, days 15.6±10.9 16.3±11.4 0.33 
Mortality% 34 16 0.00 
 
RBC TRANSFUSIONS: 
Overall, 307 patients (38%) admitted to the ICU received transfusions with blood or blood 
products while in ICU. Of those who received any transfusion, 269 (34%) patients received 
one or more RBC units with or without blood products out of which, 177 (22%) patients 
received only packed cell transfusions and 92(12%) patients received packed cells along with 
other blood products like FFP, PRC and cryoprecipitate.  
As expected, the proportion of patients who received transfusions was significantly higher in 
the surgical cohort (44%) when compared with the medical patients (23%), [p<0.0001]. The 
proportion of patients who received only packed cells without blood products was higher in 
the surgical patients(29%) when compared to the medical patients(16%) as well as those 
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patients who received packed cells along with any blood product was higher in the 
SICU(25%) vs. MICU(8%). 
 
Figure 9. Packed cell transfusions in MICU and SICU 
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Indications for transfusions 
           
Fig 10.  Overall indications for packed cell transfusions 
Although the most common overall indication for transfusion in the ICUs was a drop in 
haemoglobin, when analyzed individually among the ICU, 25% of patients in the SICU were 
transfused due to fall in haemoglobin(as defined in Materials and Methods) in the absence of 
overt bleeding whereas an equal proportion of patients(23%) were transfused due to post 
surgical bleeding. In contrast, majority(19%) of patients received packed cell transfusions in 
the MICU due to fall in haemoglobin in the absence of overt bleeding when compared to a 
minor proportion of patients who received transfusion following bleeding(1%). 
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Pre Transfusion Trigger 
The mean pre transfusion haemoglobin was 7.0±1.6 g/dl (95%CI: 6.8-7.2). However the 
mean Hb pre transfusion in Medical ICU was 6.3gm% compared to 7.4gm% in the Surgical 
ICU. This difference is statistically significant (P value 0.000).  
Table 5. Mean pre transfusion haemoglobin trigger in both ICU’s. 
 MICU SICU  
 Mean(SD) 95%confidence Mean(SD) 95%confidence p value 
Hb trigger 6.3(0.9) 6.1-6.5 7.4(1.8) 7.1-7.7 0.000 
Of the 269 patients who received packed cell transfusions, 167(62%) patients had a 
pretransfusion trigger less than 7g/dl and 102(38%) patients were transfused with a trigger of 
7g/dl and greater. Of these, 89(87%) patients were from the surgical cohort and 12(12%) 
were from the medical cohort. The indications for transfusion in patients who were 
transfused at a higher threshold were bleeding(43%), drop in haemoglobin(14%), 
symptomatic(11%), surgery(9%) and sepsis(5%). 
Association between transfusion and mortality 
Overall mortality inclusive of both ICUs was 23% among those who did not receive 
transfusions and 30% among those who received one or more RBC units with or without 
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blood products across their stay in the ICU and this difference was statistically different (OR-
1.5, 95%CI=1.08-2.09, pvalue-0.016).  
When patients were separately categorized as medical or surgical patients, the association 
between transfusion and mortality continued to be significant. 
Table 6. Association between transfusion and mortality in MICU and SICU 
 MICU SICU 
Mortality OR 95%confidence p value OR 95%confidence p value 
Transfusion 2.08 1.30-3.32 0.002 2.01 1.17-3.48 0.012 
       
Association of Transfusion with ICU and Hospital length of stay 
Transfusion with blood or blood products was found to be significantly associated with a 
prolonged ICU and hospital length of stay. 
Table 7. Association of transfusion with any blood or product with ICU and hospital stay 
Any transfusion OR 95%confidence p value 
ICU length of stay 1.05 1.03-1.08 0.000 
Hospital length of stay 1.02 1.01-1.03 0.001 
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There was a statistically significant association between receipt of packed cell transfusions 
(with or without any blood product) and prolonged ICU and hospital stay in overall ICU 
patients (Table 8) 
Table 8. Association of packed cell transfusions with ICU and hospital stay 
Transfusion OR 95%confidence p value 
ICU length of stay 1.06 1.03-1.09 0.000 
Hospital length of stay 1.02 1.01-1.03 0.002 
In the Medical ICU, a trend of longer ICU stays was noted in patients who had greater 
number of red cell transfusions (Fig 11). However this analysis could not be done in the 
surgical ICU setting as most patients had a uniformly short stay averaging 5.5± 3.9 days. 
             
                                     Fig 11. RBC transfusions across MICU stay 
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When analyzed individually, a significant association was found between packed cell 
transfusion and prolonged hospital length of stay among the medical ICU patients. However, 
such a correlation was not seen in the surgical cohort of patients, as shown in the table below. 
Table 9. Association of packed cell transfusions with hospital length of stay in MICU and 
SICU patients 
Transfusion OR 95%confidence p value 
Hospital length of stay in MICU 
patients 
1.04 1.02-1.06 0.000 
Hospital length of stay in SICU 
patients 
1.00 0.98-1.02 0.762 
 
Association of Transfusion with Age and APACHE score 
There was no significant association between age and APACHE II score between the 
transfused and non transfused groups. 
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Table 10. Association of age and APACHE II score with transfusion 
                                AGE(yrs) 
 Mean(SD) 95% Confidence p value 
No Transfusion 45±17 44-47 
0.06 
Transfusion 43±17 41-45 
 
                       APACHE II score 
 Mean(SD) 95% Confidence p value 
No Transfusion 17.6±6.8 16.9-18.2 
0.99 
Transfusion 19.7±7.6 18.8-20.6 
 
BASELINE HAEMOGLOBIN 
Overall the mean baseline haemoglobin was 10.7±2.8g/dl (Table 1). Hemoglobin level 
decreased throughout the duration of the stay in the ICU.   
The trends were similar when the ICUs were independently analyzed – as shown in the 
graphs below. The drop in haemoglobin from day 1 to day 12 in patients who were 
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transfused and not transfused were compared. The difference between these two groups of 
patients in both ICUs showed similar trends and statistically significant differences (p value 
<0.001) in both MICU and SICU. 
 
Figure 12. Haemoglobin levels from Day 1 through Day 16. Trend for remaining days of 
admission were omitted due to small number 
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Figure 13. Haemoglobin levels from Day 1 through Day 13. 
Individuals with lower baseline haemoglobin were more likely to receive an RBC transfusion 
and the difference was statistically significant. 
Table 11. Baseline haemoglobin among the transfused and non transfused. 
           HAEMOGLOBIN AT ADMISSION 
 Mean(SD) 95% Confidence p value 
No Transfusion 11.6(2.5) 11.4-11.8 
0.000 
Transfusion 8.8(2.5) 8.5-9.1 
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 MORTALITY 
There was a statistically significant association between age, APACHE II score, duration of 
ventilation and receipt of packed cell transfusion with overall mortality. However, there was 
no association between admission haemoglobin and mortality. 
Table 12. Univariate analysis for risk factors of overall mortality 
                                        MORTALITY 
 OR 95% Confidence p value 
Age 1.01 1.01-1.03 0.002 
APACHE II score 1.09 1.06-1.12 0.000 
Ventilation duration 2.51 1.54-4.11 0.000 
Hb at admission 0.96 0.90-1.01 0.135 
Transfusion 1.50 1.08-2.09 0.016 
On comparison of the risk factors in both the ICUs, there was a statistically significant 
correlation between age, APACHE II score, admission haemoglobin, duration of mechanical 
ventilation and packed cell transfusion with mortality in the medical cohort of patients. In the 
surgical cohort, a significant association was found between APACHE II score, duration of 
ventilation and packed cell transfusions with mortality but there was no association between 
age and haemoglobin at admission (Table 13). Admission haemoglobin was therefore seen to 
be significantly associated with mortality in the medical patients but not in the surgical 
cohort. 
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Table 13. Univariate analysis for risk factors of mortality in MICU and SICU 
 MICU SICU 
Mortality OR 95%confidence p value OR 95%confidence p value 
Age 1.02 1.00-1.03 0.001 1.01 0.99-1.02 0.186 
APACHE II 1.06 1.03-1.10 0.001 1.15 1.10-1.20 0.000 
Hb at admission 0.88 0.82-0.95 0.001 0.97 0.87-1.09 0.609 
Ventilation duration 2.66 1.45-4.87 0.002 2.55 1.06-6.15 0.038 
Transfusion 2.08 1.30-3.32 0.002 2.01 1.17-3.48 0.012 
 
After adjusting for other risk factors, APACHE II score and duration of mechanical 
ventilation remained statistically significantly associated with an increased risk of overall 
mortality. On the other hand, there was no significant association after adjustment with 
receipt of packed cell transfusion and mortality(Table 14a) or receipt of a transfusion with  
blood or any  blood product and mortality(Table 14b).  
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Table 14a) Multivariate analysis for risk factors of overall mortality with RBC transfusion 
 MORTALITY 
 Adj.OR 95% Confidence p value 
Age 1.01 0.99-1.02 0.149 
APACHE II score 1.08 1.05-1.11 0.000 
Ventilation duration 2.00 1.19-3.36 0.009 
Hb at admission 0.98 0.92-1.05 0.614 
RBC Transfusion 1.21 0.81-1.82 0.348 
 
 
Table 14b) Multivariate analysis for risk factors of overall mortality with any transfusion 
 
 MORTALITY 
 Adj.OR 95% Confidence p value 
Age 1.01 0.99-1.02 0.149 
APACHE II score 1.08 1.05-1.11 0.000 
Ventilation duration 2.00 1.19-3.36 0.009 
Hb at admission 0.98 0.92-1.05 0.614 
Any Transfusion              1.39          0.93-1.06             0.825 
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Comparison between ICUs, after adjustment for risk factors, revealed a statistically 
significant association between age, admission haemoglobin, duration of ventilation and 
receipt of any transfusion with blood or blood products and mortality in the Medical ICU.  
In contrast, only APACHE II score remained statistically significantly associated with 
mortality after adjustment in the Surgical ICU patients. The association between receipt of 
any transfusion and mortality was not seen following adjustment for other risk factors as 
shown in the tables below. 
Table 15a).  Multivariate analysis for risk factors of mortality with RBC transfusion in 
MICU and SICU 
 MICU SICU 
Mortality Adj. 
OR 
95% 
confidence 
p value Adj. 
OR 
95% 
confidence 
p 
value 
Age 1.02 1.00-1.03 0.005 0.98 0.96-1.00 0.154 
APACHE II 1.03 0.99-1.07 0.080 1.15 1.10-1.21 0.000 
Hb at admission 0.89 0.81-0.98 0.019 1.02 0.90-1.16 0.738 
Ventilation duration 2.57 1.33-4.97 0.005 1.44 0.56-3.71 0.448 
RBC Transfusion 1.40 0.77-2.57 0.270 1.71 0.89-3.28 0.108 
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 Table 15b).  Multivariate analysis for risk factors of mortality with any transfusion in 
MICU and SICU 
 
 MICU SICU 
Mortality Adj. 
OR 
95% 
confidence 
p value Adj. 
OR 
95% 
confidence 
p 
value 
Age 1.02 1.00-1.03 0.005 0.98 0.96-1.00 0.154 
APACHE II 1.03 0.99-1.07 0.080 1.15 1.10-1.21 0.000 
Hb at admission 0.89 0.81-0.98 0.019 1.02 0.90-1.16 0.738 
Ventilation duration 2.57 1.33-4.97 0.005 1.44 0.56-3.71 0.448 
Any Transfusion 1.92 1.07-3.45 0.028 1.81 0.94-3.52 0.078 
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SUMMARY OF RESULTS 
 
In this study 800 patients who fulfilled the inclusion criteria were recruited.  
Of these patients, 58% were males and 42% were females. The mean age of the patients was 
45±16.8years, with baseline APACHE II score of 18.30± 7.14 and a baseline haemoglobin of 
10.7±2.8. When analyzed separately, the average admission haemoglobin in patients 
admitted to the SICU was far lesser when compared to the medical cohort in MICU and the 
difference was statistically significant.  
Following admission to ICU, our study showed that 50% of the patients had haemoglobin 
levels below 10g/dl by 48hours of admission. Hemoglobin level decreased throughout the 
duration of the stay in the ICU.   
The most common indication for admission to the medical ICU in the decreasing order of 
frequency was organophosphorus poisoning(13%), Acute respiratory distress 
syndrome(11%), scrub typhus(11%), acute kidney injury(11%), septic shock(10.5%) and 
DIC(9%). 
The most common admission indications in the surgical ICU were abdominal surgery(29%), 
polytrauma(24%), pelvic surgery(15%), limb ischemia(12%), obstetric emergencies(7%) and 
thoracic surgery(6%). 
Diabetes and Hypertension were the most frequent co morbid conditions seen in 34% and 
28% respectively in the MICU and 24% and 26% respectively in the SICU.  
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81% of patients admitted to SICU and 80% of patients admitted to MICU required 
ventilatory support during their ICU stay and the duration of ventilation was higher in the 
medical cohort and it was statistically significant.  
Overall mortality rate in the ICU was 25% with mortality rates and ICU lengths of stay being 
significantly higher for the medical cohort when compared to the surgical cohort.(34%vs 
16% and 9±6 days and 5.5±3.9 days respectively, p=0.00) 
Overall, 38% of patients received transfusions with blood or blood products and 34% of 
patients received RBC transfusions. The proportion of patients who received transfusions was 
significantly higher in the surgical cohort (44%) when compared with the medical patients 
(23%), [p<0.0001]. Also,the proportion of patients who received packed cells along with any 
blood product was also higher in the SICU(25%) vs. MICU(8%). 
The overall indication for transfusion was a drop in the haemoglobin in the absence of overt 
bleeding.  
The mean pre transfusion haemoglobin was 7.0±1.6 g/dl. However the mean pre transfusion 
haemoglobin in Medical ICU was 6.3gm% compared to 7.4gm% in the Surgical ICU. 
The overall mortality inclusive of both ICUs was 23% among those who did not receive 
transfusions and 30% among those who received one or more RBC units with or without 
blood products across their stay in the ICU and this difference was statistically different. 
There was a statistically significant association between receipt of packed cell transfusions 
(with or without any blood product) and prolonged ICU and hospital stay. 
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There was a statistically significant association between age, APACHE II score, duration of 
ventilation and receipt of packed cell transfusion with overall mortality. This was particularly 
observed among the medical cohort whereas in the surgical cohort, a significant association 
was found between APACHE II score, duration of ventilation and packed cell transfusions 
with mortality. 
After adjusting for other risk factors, APACHE II score and duration of mechanical 
ventilation remained statistically significantly associated with an increased risk of overall 
mortality. On the other hand, there was no significant association after adjustment with 
receipt of packed cell transfusion and mortality. 
Comparison between ICUs after adjustment for risk factors revealed a statistically significant 
association between age, admission haemoglobin, duration of ventilation and receipt of any 
transfusion with blood or blood products and mortality in the Medical ICU. There was no 
association between receipt of a packed cell transfusion and mortality following multivariate 
analysis. In contrast, only APACHE II score remained statistically significantly associated 
with mortality after adjustment in the Surgical ICU patients. 
Even though transfusion was not an independent predictor of mortality in our study, it 
contributed to increased mortality in the presence of other risk factors in the critically ill.  
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DISCUSSION 
Worldwide, anemia is a significant problem and especially in developing countries it is very 
widespread yet the most neglected issue. India is one of the countries with highest prevalence 
of anemia in the world. It is estimated that over 50% of the Indian population is anemic. In 
the context of this, anemia in the critically ill remains an important issue.  
Many landmark studies have quantified the incidence of anemia and the use of packed cell 
transfusions in the critically ill patients. 
In our study, the mean age of the study population was 45±17years which was far lesser than 
the mean age of the patients in other studies like CRIT study (60±18years) and the ABC 
trial(61years)(75),(9).  
The majority of the patients were males which was similar to the previous studies.  
The mean APACHE II score was 18.30± 7.14, and it was similar across both the ICU‟s in the 
study population. 
The average duration of ICU stay was 7.3±5.4 days with a mean of 9.0±6.0 days in MICU 
and 5.5±3.9 days in SICU, which was similar to that observed in the CRIT study. 
Our study found that 70% of critically ill patients had a haemoglobin concentration less than 
12g/dl on admission to the ICU. This was similar to the ABC trial which showed that 63% of 
critically ill patients had a haemoglobin concentration less than 12g/dl on admission to the 
ICU. Following admission to ICU, our study showed that 50% of the patients had  
82 
 
haemoglobin levels below 10g/dl by 48hours of admission. Another audit of transfusion 
practice in the United Kingdom following the TRICC study found  haemoglobin 
concentration less than 9g/dl in 55% of all patients who stayed more than 24hours in the ICU 
and it also occurred early, on the first and second ICU days in 52% and 77% of these 
patients.(79) 
The anemia in these patients persisted throughout the duration of their ICU stay. This finding 
was consistent with previous studies like The CRIT Study wherein by 48hours after ICU 
admission, 70% of patients had a baseline haemoglobin less than 12g/dl and half of these 
patients had a haemoglobin less than 10g/dl. 
Transfusion practice in response to anemia was consistent with other studies. RBC 
transfusions during the ICU period was 34%, which was similar to the ABC trial (37%) and 
the SOAP study (33%) (75).  
In our study population, the surgical ICU patients received more RBC transfusions when 
compared to their medical cohort (44% vs. 23%) which was observed in the study by 
Groeger et al(80). 
The mean pre transfusion trigger observed was 7.0±1.6g/dl, a value that is comparable to the 
TRICC study(42). This was lower than that observed by the CRIT(8.6±1.7g/dl) and ABC 
trial(8.4±1.3g/dl).  
The most common indication for packed cell transfusion was low haemoglobin which was 
comparable to the CRIT study and ATICS study(76).  
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Individuals with lower baseline haemoglobin were more likely to receive an RBC transfusion 
when compared to those who did not receive transfusion and the difference was statistically 
significant (11.6±2.5 vs. 8.8±2.5g/dl, p value-0.000). 
There was no significant association between age and receipt of transfusion across ICUs. 
The association between transfusion rates and degree of organ failure, as assessed by the 
APACHE II score, was also analyzed. The baseline APACHE II score was not statistically 
different between the transfused and non transfused patients. 
Transfusion was associated with a longer duration of ICU stay (OR-1.06, 95%CI:1.03-1.09). 
 It was also associated with a prolonged hospital length of stay when analyzed overall but on 
comparison within ICUs, it was noticed that packed cell transfusions were associated with a 
prolonged hospital stay only in the medical cohort of patients (OR-1.04, 95%CI:1.02-1.06, p 
value-0.000), whereas such a correlation was not seen among the surgical ICU  patients (OR-
1.00, 95%CI:0.98-1.02, pvalue-0.762).  
Transfused patients had a higher ICU mortality rate than the non transfused patients (30% vs. 
23%, p value- 0.015).  
Receipt of a transfusion in the ICU increased a patient‟s odds of dying by a factor of 1.50 
(95% confidence interval, 1.08-2.09). This fact was observable in the other studies like the 
ABC trial (OR-1.37, 95% CI: 1.02-1.84) and the TRICC study where the mortality rates 
during ICU and hospitalization were lower in the restrictive strategy when compared to the 
liberal strategy group. In contrast, the SOAP study showed that blood transfusions were not 
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associated with increased mortality by multivariate analysis or propensity matching and an 
extended Cox proportional hazard analysis showed that patients who received a transfusion 
had a better survival. 
A logistic regression model was used to adjust for differences in all observed background 
characteristics in the estimation of the effects of transfusion.  
Variables chosen were age, APACHE II score, admission haemoglobin, ventilation duration 
and receipt of transfusion. The model showed that blood transfusion was not an independent 
risk factor associated with a worse mortality rate (OR-1.21, 95%CI:0.81-1.82,p value-0.348), 
an observation similar to the SOAP study.  
This model also showed that the associations of APACHE II score and ventilation duration 
with mortality were statistically significant but age and admission hemoglobin level was not.  
When the model was created independently for each ICU, it was observed that that the 
association between age, admission haemoglobin, ventilation duration and receipt of any 
transfusion with mortality remained statistically significant in the MICU patients whereas 
only APACHE II score remained significantly associated with mortality in the SICU patients. 
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Table16 : Comparison of data of current study with other studies 
*NS: not specified 
 Year conducted, 
Country 
No of patients 
and number of 
ICUs 
Percentage 
transfused in 
ICU 
Commonest indication 
for transfusion 
Pre transfusion 
haemoglobin level 
Percentage 
ICU mortality 
Current Study 
 
2012-2013, 
India 
800 patients in 
2 ICUs 
34.0% Low haemoglobin 7.0±1.6g/dl 25% 
CRIT Study 
(Corwin et al) 
2000-2001 
USA 
4,892 patients 
in 284 ICUs 
44.0% Low haemoglobin 8.6±1.7g/dl 18% 
ABC trial 
(Vincent et al) 
1999, 
Western Europe 
3,534 patients 
in 146 ICUs 
37.0% Acute bleeding 8.4±1.3g/dl 13.5% 
ATICS Study 
(Walsh et al) 
2001, 
Scotland 
1,023 patients 
in 10 ICUs 
39.5% Acute bleeding 7.8g/dl 25% 
SOAP Study 
(Vincent et al) 
2002, 
Europe 
3,147 patients 
in 198 ICUs 
33% NS* NS* 23.7% 
Australasian study 
(Westbrook et al) 
2008, 
Australia and New 
Zealand 
5,128 patients 
in 47 ICUs 
14.7% Improve oxygen 
delivery 
7.7g/dl NS* 
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CONCLUSION 
Anemia is a common finding in the critically ill patients.  
The most common indication for RBC transfusion is to treat the low haemoglobin rather 
than acute bleeding.  
As demonstrated in other studies, we also found a significant drop in the haemoglobin 
during ICU stay both in the surgical ICU as well as in the medical ICU when analyzed 
individually. 
Many studies including ours have shown that most critically ill patients can be managed 
with a haemoglobin threshold of 7g/dl, below which packed cell transfusions can be 
initiated.  
Although transfusions can be lifesaving, many studies including ours have reported that 
the risks of transfusion outweigh the benefits.  
Mortality in the transfused was significantly higher than in the non transfused and receipt 
of a transfusion in the ICU increased the odds of dying by a factor of 1.5 when analyzed 
overall. However, comparison between ICUs after adjustment of other risk factors 
revealed a statistically significant association in the medical ICU between receipt of any 
transfusion with blood or blood products with mortality. In contrast, such an association 
was not seen in the surgical cohort. 
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Transfusion also led to prolonged ICU and hospital length of stay. There was a significant 
association in the medical patients but it was not observed with their surgical 
counterparts. 
Even though transfusion was not an independent predictor of mortality in our study, it 
contributed to increased mortality in the presence of other risk factors in the critically ill.  
Therefore approaches should be made to reduce RBC transfusions and the need for 
transfusions should be individualized based on the patient‟s clinical circumstances rather 
than a subjective haemoglobin concentration. 
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ANNEXURES 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
ANNEXURE I 
 
  
            
 
 
 
 
 
 
ANNEXURE II 
 
                                                                    
 
Primary  diagnosis: 
Type of surgery: 
APACHE Score: 
 
 
 
H/O recent blood loss: Y/N 
 
 
 
 
H/O any recent treatment with recombinant erythropoietin/haematinics/blood 
transfusion: 
 Haemoglobin levels: 
 Admission Day1 Day2 Day3 Day4 Day5 Day6 Day7 Day8 Day9 
Hb 
levels:  
 
          
 
Indication for transfusion: (√)If present 
Bleeding  Drop in Hb Sepsis Ischemic Hypotension Symptomatic Surgery 
       
ANEMIA AND TRANSFUSION DECISIONS IN INTENSIVE CARE UNITS 
Comorbidities: (√)If present 
Diabetes  
Hypertension  
IHD  
C Kidney Disease  
Sepsis  
Others(Mention)  
 
Name:  Age:  Sex:  Hospital No:  
 
 
 
 
Transfusion trigger and Number of RBC units transfused: 
 
 
 
 
 
 
 
 
 
Other components transfused: 
 
 
 
 
 
 
 
 
Outcome of ICU stay: (√) If present 
Discharged  
Death  
 Number of ventilated days: 
Number of days of ICU stay: 
Total length of hospital stay: 
Date of 
Transfusion 
             
Time of 
Transfusion 
             
Transfusion 
Trigger 
             
Type of 
Unit
†
 
             
No. of units              
 
†Whole Blood- WB, LDRC-leukocyte depleted red cells, RC-Rejuvenated cells 
Date of 
Transfusion 
         
Type of 
Component
‡
 
         
No. of units 
Transfused 
         
Indication          
 
‡ FFP(Fresh Frozen plasma) , PRC(Platelet rich concentrate), SDP(Single donor platelets),   
CP(Cryoprecipitate) 
 
